



DEVELOPING COMMERCIAL OUTCOMES

CEO AGM 2022 Presentation

Julie Phillips | CEO and Director, BioDiem Ltd

SAFE HARBOUR STATEMENT

This presentation is provided to you for information purposes only and should not be construed as investment advice or an offer, and shall not form part of an offer, or solicitation to buy or sell any securities or derivatives. It should not be considered as an invitation to subscribe for or purchase any securities in Opal Biosciences Limited (“Opal”) or BioDiem Limited (“BioDiem”), or as an inducement to make an offer or invitation with respect to those securities. No agreement to subscribe for securities in BioDiem or Opal will be entered into on the basis of this presentation.

This presentation contains forward-looking statements which are based on an assessment of present economic and operating conditions, and on a number of assumptions regarding future events and actions that, at the date this presentation was prepared, are expected to take place. Such forward looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of BioDiem or Opal. BioDiem or Opal cannot and do not give any assurance that the results, performance or achievements expressed or implied by the forward looking statements contained in this presentation will actually occur and you should not place reliance on these forward looking statements.

To the maximum extent permitted by applicable laws, BioDiem or Opal and its affiliates make no representation and can give no assurance, guarantee or warranty, express or implied, as to, and take no responsibility for the authenticity, validity, accuracy, suitability or completeness of, or any errors in or omission, from any information, statement or opinion contained in this presentation.

The contents of this presentation are confidential. The presentation is being provided to you on the condition that you do not reproduce or communicate it to, or disclose it to, or discuss it with, any other person without the prior written permission of BioDiem or Opal .

FY2022 Highlights




Income from royalties, milestone and consulting fee payments totalling \$403,184



Changchun BCBT Biotech Co extension of licenced territories; Serum Institute approval of quadrivalent LAIV



Board changes with retirement of Mr Hugh Morgan AC and addition of Mr Damien Hannes as chairman



Company strategy re-focus: to establish Australian small-scale manufacturing facility for clinical trial supplies



Article

Safety and Viral Shedding of Live Attenuated Influenza Vaccine (LAIV) in Chinese Healthy Juveniles and Adults: A Phase I Randomized, Double-Blind, Placebo-Controlled Study

Li Li ¹, Nianmin Shi ², Na Xu ³, Haibin Wang ¹, Hui Zhao ⁴, Haidong Xu ⁵, Dawei Liu ³, Zheng Zhang ¹, Shuping Li ¹, Junnan Zhang ¹, Chunhui Guo ⁶, Jinglei Huo ⁷, Menghan Zhao ⁵, Fengji Luo ⁸, Liqing Yang ¹, Yunhua Bai ¹, Qiang Lu ⁸, Yusong Zhang ¹, Yi Zhong ¹ and Wenhui Gao ^{1,*}

- ¹ Chaoyang District Center for Disease Control and Prevention, No. 25 Huaweili, Panjiayuan, Chaoyang District, Beijing 100021, China
 - ² Vaccine Clinical Research Branch of China Association for Vaccines, No. 11, Xinzhong St., Dongcheng District, Beijing 100010, China
 - ³ Changchun BCHT Biotechnology Co., No. 138 Zhuoyue St., Gaoxin District, Changchun 130012, China
 - ⁴ National Institutes for Food and Drug Control, No. 31, Huatuo Avenue, Daxing Biomedical Complex, Daxing District, Beijing 102600, China
 - ⁵ Jinsong Community Health Service Center, No. 501, Jinsong St., Chaoyang District, Beijing 100020, China
 - ⁶ Baotou Medical College, No. 31 Jianshe Rd., Donghe District, Baotou 014000, China
 - ⁷ Xiangheyuan Community Health Service Center, No. 15 Liufang St., Chaoyang District, Beijing 100020, China
 - ⁸ Beijing Institute of Biological Products, No. 13, South East Third Ring Rd., Chaoyang District, Beijing 100021, China
- * Correspondence: cyqwjwcdcgwh@bjchy.gov.cn



Influenza Vaccine Manufacturers (2021)

| Manufacturer | Type of Vaccine | Inoculation Method | Specification (mL) | User Group | Dose of Vaccination | Time to Market |
|--|------------------------------------|--------------------|--------------------|------------|---------------------|----------------|
| Fosun Pharmaceutical | Trivalent split | Intramuscular | 0.25/0.5 | 6M-3Y/>3Y | 2/1 | 2005 |
| Sanofi China | Trivalent split | Intramuscular | 0.25/0.5 | 6M-3Y/>3Y | 2/1 | 2013 |
| Adimmune Corporation | Trivalent split | Intramuscular | 0.25/0.5 | 6M-3Y/>3Y | 2/1 | 2015 |
| Zhongyianke Biotech. Co., Ltd. | Trivalent subunit | Intramuscular | 0.5 | 3Y | 1 | 2010 |
| Changchun BCHT Biotechnology Co. | Trivalent attenuated (nasal spray) | Spray | 0.2 | 3-17Y | 1 | 2020 |
| Hualan Biological Engineering, Inc. | Trivalent split | Intramuscular | 0.25/0.5 | 6M-3Y/>3Y | 2/1 | 2011/2008 |
| | Tetavalent split | | 0.5 | >3Y | 1 | 2018 |
| Sinovac Biotech Ltd. | Trivalent split | Intramuscular | 0.25/0.5 | 6M-3Y/>3Y | 2/1 | 2005 |
| | Tetavalent split | | 0.5 | >3Y | 1 | 2020 |
| Changchun Institute of Biological Products Co., Ltd. | Trivalent split | Intramuscular | 0.25/0.5 | 6M-3Y/>3Y | 2/1 | 2007/2004 |
| | Tetavalent split | | 0.5 | >3Y | 1 | 2020 |
| Shanghai Institute of Biological Products Co., Ltd. | Trivalent split | Intramuscular | 0.25/0.5 | 6M-3Y/>3Y | 2/1 | 2004/2001 |
| | Tetavalent split | | 0.5 | >3Y | 1 | 2021 |
| GDK Biotechnology Co., Ltd. | Tetavalent split | Intramuscular | 0.5 | >3Y | 1 | 2019 |
| Wuhan Institute of Biological Products Co., Ltd. | Tetavalent split | Intramuscular | 0.5 | >3Y | 1 | 2020 |



--- Mucosal Immunity + Humoral Immunity + Cellular Immunity ---

INFLUENZA VACCINE, LIVE, NASAL, FREEZE-DRIED

Good Safety: 【Free of Inactivator, Split Agent and Preservative】

Indicated for Age Groups from 3 Years-17 Years



Intranasal spray administration - No injection and no pain

Mucosal immunity - Fast antibody production

Cross immunity - Better efficacy



Central Drugs Standard Control Organization


Directorate General of Health Services
Ministry of Health & Family Welfare
Government of India



Details of manufacturing permissions of Human Vaccines approved by CDSCO (2009 to 2022)

Year: 2021

| | | | | |
|-----|---|---|---|---------------------------------------|
| 24. | M/s Serum Institute of India Pvt. Ltd. 212/2, Off Soli Poonawalla Road, Hadapsar, Pune, Maharashtra (India)- 411028 | Influenza Vaccine (Human, Live Attenuated) I.P., Quadrivalent | For active Immunization against influenza disease caused by two influenza A subtype viruses and two influenza Type B viruses in the age group of 2 years and above. | MF/BIO/21/000139 Dated 30-Dec-2021 |
|-----|---|---|---|---------------------------------------|



<https://cdsco.gov.in>



An Australian biotechnology company focused on growing Australia's vaccine and pharmaceutical development and manufacturing capability



FY22 Highlights



\$250,000 placement in Sep 2021;
\$162,431 raised from option exercise;
\$87,569 raised from placement post-year end



Company strategy re-focus: to establish Australian small-scale manufacturing facility for clinical trial supplies



Three grant applications lodged to support new strategy (partners Formulytica Pty Ltd; University of Western Australia)



Board change: Mr Hugh Morgan AC and Mr Peter Snowball retire from the board; Mr Damien Hannes(chairman of BioDiem Ltd) joins as a non-executive director



Company focus HY21: GSK site

EOI lodged 18 Mar 2021

- New site owner announced & discussions opened (June '21) to create a life sciences precinct
- Discussions undertaken with governments, industry groups, local and international companies, universities, the site owner and others to develop a business plan for the site.
- Submission of grant applications

2025 Growth Vision
– Boronia Biotech
Precinct

*- full onshore development and
manufacture capability*



Company focus CY22: Perth site

- Perth manufacturing site
- WA visit – potential facility sites, UWA, WA government (May 2022)
- Medical Research Future Fund (MRFF): mRNA Clinical Trial Enabling Infrastructure grant
 - Professor Archa Fox (University of Western Australia) contacted
 - Western Australian (WA) government contacted
 - Grant application finalized and submitted 15 Jul 2022
- Medical Research Future Fund (MRFF): National Critical Research Infrastructure grant
 - Grant application finalized and submitted 7 Sep 2022
- Western Australian Investment Attraction Fund EOI submitted (May 2022)
 - Invited to submit final application (Aug 2022)
 - Full application finalized and submitted (Oct 2022)


Results awaited.




Project Overview

- Small scale pharmaceutical manufacturing facility
- Fee-for-service operation
 - Manufacture to meet relevant global regulatory standards
- Focus on personalised/precision medicine
- Novel mRNA lung cancer vaccine candidate development with partners UWA and Formulytica Pty Ltd

mRNA vaccine targeting lung cancer



mRNA vaccine targeting lung cancer









Lead candidate production for clinical testing



New sterile facility for advanced manufacture

- small scale topical and injectable products
- development and manufacture incl for clinical trials





Outlook for FY23

- Grant funding
- Partnership with Formulytica Pty Ltd
- Capital raise for balance of funding (as required)
- Execute plan to **establish small scale manufacturing capability for sterile liquid products including vaccines.**





DEVELOPING COMMERCIAL OUTCOMES

CEO AGM 2022 Presentation

Julie Phillips | CEO and Director, BioDiem Ltd